imiquimod has been researched along with vtx-2337 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dietsch, GN; Disis, ML; Ghanekar, S; Henderson, KE; Hershberg, RM; Howbert, JJ; Inokuma, M; Lu, H; Maino, VC; Matthews, MA; Suni, M; Yang, Y | 1 |
1 other study(ies) available for imiquimod and vtx-2337
Article | Year |
---|---|
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.
Topics: Aminoquinolines; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Benzazepines; Dendritic Cells; Drug Synergism; HEK293 Cells; Humans; Imiquimod; Inflammation Mediators; Interferon-gamma; Interleukin-12; Killer Cells, Natural; Leukocytes, Mononuclear; NF-kappa B; Oligodeoxyribonucleotides; Polymorphism, Single Nucleotide; Receptors, IgG; Rituximab; Toll-Like Receptor 8; Tumor Necrosis Factor-alpha | 2012 |